Full-Time

Clinical Sales Manager

Karius

Karius

201-500 employees

Non-invasive liquid biopsy for infectious pathogens

Compensation Overview

$118.3k - $177.5k/yr

Seattle, WA, USA

In Person

Category
Sales & Account Management (2)
,
Required Skills
Sales
Salesforce
Requirements
  • Bachelor’s degree.
  • Five years of sales or business development experience in the Life Sciences, Biotechnology, Medical Device, Diagnostic Equipment, or Pharmaceutical industries.
  • Valid driver's license.
  • Previous experience introducing transformational or novel products to physicians and hospitals prior to significant peer-reviewed publications or inclusion in clinical guidelines.
  • Existing network of relationships in hospitals and health systems, including microbiology labs, send-out labs, physician groups, C-level executives, and clinical administrators.
  • Demonstrated track record of meeting and exceeding sales objectives.
  • Experience with multi-level account management.
  • Ability to travel up to 70 percent of the time.
Responsibilities
  • Grow sales revenue and test volume in the Pacific Northwest territory by establishing new business and increasing volume in existing hospital accounts.
  • Engage key hospital stakeholders involved in the decision process for implementing new diagnostic tests.
  • Collaborate with Inside Sales, Customer Success, Medical Affairs, and Marketing teams to achieve territory and company goals.
  • Develop thought leaders and early adopters for the Karius infectious disease diagnostic approach.
  • Prioritize and segment hospital and health system accounts to maximize growth opportunities.
  • Present product features and benefits to clinical call points using consultative sales techniques including qualifying leads, assessing needs, and supporting evaluations.
  • Manage early evaluations to activate initial adoption and drive increased utilization of Karius solutions over time.
  • Serve as a subject matter expert to clinicians regarding the science and technology of the Karius test and its clinical differentiation.
  • Build and maintain relationships across multiple stakeholders to drive consensus among prospective and existing partners.
  • Demonstrate Return on Investment to partner accounts and conduct regular utilization reviews.
  • Secure and manage renewals of partner agreements and contracts to memorialize long-term relationships.
  • Provide market feedback to Sales, Marketing, and Product leadership to inform business functions.
  • Partner with Clinical and Medical Affairs teams to support remote and in-person partner interactions.
  • Collaborate with Customer Success to onboard new accounts, address risks, and monitor the health of partner relationships.
  • Identify and co-manage regional meeting opportunities and develop Key Opinion Leader panels.
  • Participate in sales meetings, training programs, conventions, and industry trade shows.
  • Complete administrative duties including documentation in Salesforce, expense reporting, and speaker program information.
Desired Qualifications
  • Advanced degree or Master of Business Administration.

Karius provides rapid, non-invasive infectious-disease diagnostics using the Karius Test, a liquid biopsy that detects over 1,000 pathogens from a single blood sample. The test analyzes microbial cell-free DNA circulating in the bloodstream, using advanced genomics and artificial intelligence to identify pathogens. It operates on real-time genomic data and a constantly updated reference database, enabling clinicians to diagnose infections without multiple invasive tests. Unlike traditional methods, Karius combines a broad pathogen panel with machine-learning analysis to deliver faster results and reduce unnecessary procedures. The company's goal is to help healthcare providers diagnose infections quickly, improve patient outcomes, and reduce healthcare costs by offering a faster, less invasive diagnostic option.

Company Size

201-500

Company Stage

Series C

Total Funding

$345M

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Designation expedites Karius Test approval for lung infections.
  • $100M Series C funding in May 2024 expands beyond 400 U.S. hospitals.
  • Test incorporated into 2023 Duke-ISCVID Criteria for infective endocarditis.

What critics are saying

  • Arcadia Biomed captures market share with faster plasma cfDNA test in 2025.
  • Illumina DRAGEN app enables in-house sequencing, eroding lab revenues by Q2 2025.
  • Day Zero Diagnostics displaces Karius in sepsis contracts through 2026.

What makes Karius unique

  • Karius Test detects over 1,000 pathogens via microbial cell-free DNA from single blood draw.
  • Proprietary AI analyzes genomic data in real-time for rapid infectious disease diagnosis.
  • CLIA-certified lab provides non-invasive liquid biopsy for immunocompromised patients.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Karius who can refer or advise you

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Business Wire
May 16th, 2024
Karius Test® Receives Fda Breakthrough Device Designation To Aid In The Diagnosis Of Infectious Disease

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc., a leader in genomic diagnostics for infectious diseases, announced today that the Karius Test® has been granted designation as a Breakthrough Device from The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA), for use in the diagnosis and management of immunocompromised patients with suspected lung infections including lower respiratory infection and pneumonia. “The Karius Test is commercially available nationwide as a laboratory developed test. We are seeking FDA marketing authorization of the Karius Test for lung infections in immunocompromised patients because improved diagnostic tests are urgently needed for these patients,” stated Brad Perkins, M.D., Chief Medical Officer of Karius. “As noted in the American Thoracic Society (ATS) Workshop Report for Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria,1 lung infections have high morbidity and mortality in immunocompromised patients, which is why advances in technologies like metagenomic sequencing used for the Karius Test are vital in improving the diagnosis and treatment of these patients.”. The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these innovative medical devices

Forbes
May 8th, 2024
Innovationrx: Deepmind Unveils Its New Protein-Folding Ai Model Alphafold 3

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. A protein folding prediction in response to a small molecule generated by AlphaFold 3.Isomorphic LabsToday, Deepmind announced the launch of AlphaFold 3, the next generation of its AI software for structural biology, which has enabled thousands of researchers to predict the complicated chemical interactions involved with proteins. One major difference in the new iteration of the program: instead of just predicting protein folding, it predicts the interactions of other biological molecules as well including DNA, RNA and small molecules. The company published the accuracy of its predictions in the journal Nature.In addition to the new capabilities–which even includes the ability to make predictions based on epigenetic changes to DNA–the company has also launched AlphaFold Server, a web service that enables researchers to generate biochemical models without having to install the system itself from open source code, as was the case with previous iterations. Something else new is that AlphaFold now works with diffusion models – which are popularly known for being used by AI systems that generate images from text prompts – in place of some of its previous structural models.“The response to AlphaFold 2 was more than I could have ever imagined in terms of the kind of creativity and what the research community has done with it,” Deepmind research director John Jumper said at a press briefing

CityBiz
May 3rd, 2024
Karius Secures $100M in Series C

Karius, Inc., a genomic diagnostics company, has raised $100 million in a Series C funding round co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare. The funds will be used to expand the reach of the Karius Test®, which detects over 1,000 pathogens from a single blood sample, beyond 400 U.S. hospitals. The company also added three new board members, including Alex Morgan from Khosla Ventures, Joep Muijrers from Gilde Healthcare, and Andrew Booth from 5AM Ventures.

RamaOnHealthcare
May 2nd, 2024
Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test

Karius secures $100M to expand non-invasive pathogen blood Test.

Business Wire
May 2nd, 2024
Karius Secures $100M for Genomic Diagnostics Expansion

Karius, Inc. has raised $100M in Series C funding, co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, with participation from Seventure Partners and others. The funds will expand the reach of the Karius Test®, a genomic diagnostic test for infectious diseases, beyond 400 U.S. hospitals. The investment also supports research into microbial cell-free DNA technology. Additionally, Karius announced three new board members.